Key facts
- It has raised $6.7M; the latest was Early Stage VC in Mar 2025.
- Notable investors include Fosun Health Capital, Shanghai Creation Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Celregen Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Celregen Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Celregen Therapeutics
Provider of platform-based solutions designed for cell therapy and regenerative medicine. The company focuses on building advanced technologies, including rapid iPSC reprogramming, a patented CRISPR/Cas12b-based iPSC gene-editing platform, and bioinformatics-guided differentiation techniques across different germ layers, providing comprehensive upstream and downstream R&D processes for iPSCs and their derivative products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Website
- celregen.com/
- Ownership
- Privately Held (backing)
Celregen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celregen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celregen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.